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Abstract
The high rate of recurrence of urinary stones after initial treatment makes metaphylaxis 
essential in children. Thorough assessment and planning prior to metaphylaxis enable 
accurate and effective treatment. Expected benefits and possible adverse conditions must 
be considered when deciding on dietary restrictions in growing children, as their bone 
development is ongoing. A diet that includes abundant hydration and avoids salt pro‐
duces the optimal cost‐benefit ratio. When dietary modification is not sufficient, medical 
treatment must be added.
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1. Introduction
The high rate of recurrence of urinary‐stone disease indicates the necessity of metaphylaxis, 
especially in children. All lifestyle changes and medications for prevention of stone disease 
define the stone metaphylaxis. After stone treatment, even stone‐free children showed a 25% 
recurrence rate during a three‐year follow up [1]. In addition, after the urinary tract stone 
surgery, the rate of stone recurrence over five years has been observed to vary from 38 to 
65% depending on the malformation of the urogenital system [2]. Children with metabolic 
disorders had a higher recurrence rate, so metabolic examination is essential to preventive 
treatment in children. In the pediatric age group, the most common metabolic disorders are 
hypercalciuria and hypocitraturia, with hypercalciuria more often found in the endemic areas 
and hypocitraturia in the nonendemıc areas [3, 4]. Metaphylaxis has been found to reduce 
recurrence rates by about half, even in recurrent kidney stones [5].
Proper metaphylaxis must be preceded by a complete metabolic evaluation. In addition, 
identification of any anatomical abnormalities that may increase the risk of nephrolithiasis, a 
detailed dietary history, patient and family medical history, and a record of any medications 
used must be obtained [6].
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The European Association of Urology (EAU) guidelines recommend metabolic assessment 
based on the type of the stones, which may be obtained spontaneously or after pediatric uro‐
lithiasis treatment [6]. However, it is not always possible to obtain stones with minimally 
invasive surgery, particularly in patients undergoing retrograde intrarenal surgery and shock 
wave lithotripsy (SWL). In this case, a general screening is required. The EAU’s pediatric 
urology guidelines recommend biochemical testing, including serum urea, creatinine, elec‐
trolytes, phosphorus, alkaline phosphate, uric acid, total protein, and albumin. If hypercalce‐
mia is identified, the level of parathormone should be measured [6]. The ratio of spot urine 
calcium to creatinine should be analyzed, including a urinalysis and urine culture. Calcium, 
phosphate, magnesium, oxalate, uric acid, citrate, cysteine, protein, and creatinine clearance 
must be measured in a 24‐hour urine [6]. In some cases, the test can be customized based on 
the stone type.
Renal tubular acidosis (RTA) should be suspected in calcium stones with urine pH that repeat‐
edly tests higher than 5.5 [7]. In such patients, blood‐gas levels must be analyzed. A urine pH 
consistently testing lower than 6 may indicate an acidic arrest [7].
Any renal anomaly responsible for the stones should be treated if there is a treatable pathol‐
ogy, including ureteropelvic junction obstruction. The child’s diet must be reviewed for risk 
factors, including anorexia, high salt intake, and excessive sugar intake. Metaphylaxis must 
take into consideration medically necessary diets, including ketogenic diets.
Urolithiasis of 1–2% is associated with use of some medications [8]. Detecting such risks in the 
medical history is important for proper treatment planning. Vitamins C and D, loop diuretics, 
carbonic anhydrase inhibitors, and laxatives affect the metabolism and may lead to stone for‐
mation. The mechanisms by which these drugs potentiate stone formation and the treatment 
approaches pertinent to them will be discussed later in this chapter [8]. Magnesium trisili‐
cate, commonly used for gastroesophageal reflux, causes silica stones, and ciprofloxacin, sul‐
fonamide, triamterene, indinavir, and ceftriaxone form stones [8–10] that are radiolucent or 
semiopaque [8]. Stones that are weakly opaque or nonopaque and for which analysis results 
cannot be obtained should be suspected as drug‐induced calculi.
Excessive use of laxatives causes formation of ammonium acid urate stones. Low urine vol‐
ume and the low pH associated with chronic diarrhea increase the ammonium in urine [8]. In 
addition, anorexia, which is usually a postpuberty disease, is a cause of urolithiasis, with 5% 
of anorexia patients forming kidney stones [11], which are usually calcium oxalate, but which 
may be ammonium urate [12, 13]. The latter being stones that develop in cases of decreased 
urinary output, increased urine ammonium with hypophosphaturia, and the hyperchloremic 
acidosis associated with diarrhea [14]. Anorexia and any other identified primary disease 
should be treated before metaphylaxis.
Loop diuretics are commonly used to treat pulmonary disorders in newborns and act on 
the Na+‐K+‐2Cl pump through the thick part of Henle’s loop, inhibiting the reabsorption of 
magnesium and calcium with the reabsorption of sodium [15]. In infants, due to their low glo‐
merular filtration rates and immature hepatic development, the half‐life of drugs is 6–20‐fold 
longer, the clearance is 1.2–1.4‐fold lower, and volume distribution is 1.3–6‐fold broader than 
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in adults [15]. In addition, the half‐life is further increased in premature infants, with a half‐
life that is 6 hours in term infants and as long as 67 hours in premature infants [16]. However, 
increased knowledge of the pharmacokinetics and complications of using loop diuretics in 
infants have decreased the incidence of stones associated with these drugs [17, 18].
2. Diet
2.1. Fluid intake
Metaphylaxis of urinary stones may primarily involve regulating fluid intake and diet. 
Although hydration has been shown to decrease stone recurrence, the effectiveness of nutri‐
tion is controversial [19]. Increased fluid intake increases urine volume and inhibits crystal 
supersaturation and crystallization. In children, the fluid intake required for adequate uri‐
nary output must be calculated over 1.5 l/m2of body area [7]. Sweet‐flavored liquids should 
be avoided, since fluid containing glucose and fructose increase excretion of calcium and 
oxalate [20]. In addition, fluid intake must be distributed over the entire day. Consequently, 
in metaphylaxis of stones, water intake is the approach that has the optimal cost‐benefit ratio 
[21]. However, it is not possible to monitor the fluid intake of children in school, and chil‐
dren’s compliance in hydration is poor in general [22]. Because the need for liquids varies 
with temperature and activity level, parents may be recommended to monitor hydration 
based on urine color and urine density, if possible. Urine densities that repeatedly measure 
higher than 1010 indicate inadequate fluid intake [22].
2.2. Nutrition
Eating fast foods and processed foods can potentiate increased salt intake, causing hyper‐
volemia, which leads to decreased absorption of water and sodium through the proximal 
tubules. This, in turn, decreases the absorption of calcium by sodium in the proximal tubules, 
which increases the level of calcium in the urine. The concentration of sodium in the urine 
is in proportion to dietary salt intake. In turn, dietary salt intake is in direct proportion to 
the calcium excreted in the urine [23]. In a Western‐type diet, salt intake is almost 9 g/day in 
adults, nearly 77% of which comes from processed foods [24]. In contrast, daily salt intake 
should be below 3 mEq/kg [25]. Therefore, children’s consumption of fast foods should be 
limited to decrease dietary salt intake.
Only 10–20% of oxalate in the urine is associated with diet [26]. However, oxalate absorption 
through the bowels is related to dietary calcium intake [27], and restricting dietary calcium 
increases urinary excretion of oxalate. However, restricting salt decreases oxalate, and more 
significantly, the calcium excreted in the urine of those with calcium‐oxalate stones [28].
Oxalate is the product of vitamin C metabolism and is excreted in urine [29]. Therefore, 
increased vitamin C intake may lead to hyperoxaluria. Children with hyperoxaluria should 
decrease consumption of high‐oxalate foods [6]. In addition, oxalobacter formigenes, a probi‐
otic, decreases urinary oxalate and is effective against hyperoxaluria [30].
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Animal proteins increase the acid load, the excretion of calcium, and decrease the excretion of 
citrate [25]. In addition, purine metabolism increases uric acid [25], which increases the risk of 
calcium stones through epistaxis [31]. Despite all this, the protein restrictions recommended 
for adults are not suitable as part of stone metaphylaxis in children and adolescents, except in 
cases of definite indications [6].
Urinary excretion of citrate is affected by the system’s acid‐base balance. Although acidosis 
decreases renal excretion of citrate and increases its reabsorption, the opposite is true in alka‐
losis [32]. A Western‐type diet that includes decreased consumption of fruits and vegetables 
and increased consumption of animal products causes metabolic acidosis, resulting in lower 
urine pH and hypocitraturia [33]. Hypokalemia also lowers urine pH, and low potassium 
intake decreases urine potassium and citrate in hypokalemia and increases urinary excretion 
of calcium [32, 34]. Systemic alkalization increases excretion of citrate, decreases excretion of 
calcium, and raises urine pH [35]. Oranges, lemons, limes, and some types of mandarins are 
natural sources of citrate [35]. Alkaline fruits, including melons, cause urinary alkalization 
[36]. Grapefruits increase excretion of both citrate and oxalate [37]. The lithogenic effects of 
grapefruit juice and apple juice are controversial [38, 39].
Metaphylaxis benefits may be provided by increasing hydration and citrus intake and 
decreasing intake of sodium, oxalate, animal protein, and fructose [32]. Cranberry juice is 
high in oxalate and, therefore, increases urinary calcium and oxalate and decreases uric acid 
concentration. However, cranberry juice acidifies the urine, resulting in increased formation 
of calcium‐oxalate and urate stones but decreased formation of calcium‐phosphate stones 
[40]. Since cranberry juice acidifies the urine, it may be useful for infection stones that have 
limited options for medical treatment [41].
A study of 42,859 adults showed that high coffee and tea intake decreased the risk of symp‐
tomatic stone formation [39]. A more recent study of 6033 adults suggested that coffee intake 
decreased urine oxalate and uric acid, increased urine calcium and potassium, and also 
decreased the supersaturation of calcium oxalate by increasing urine volume [42]. However, 
dietary intake of coffee and tea cannot be recommended for pediatric patients because of the 
lack of studies of these substances in children.
Potential renal acid load (PRAL) is used to calculate the acid load of foods in adults. However, 
renal net acid excretion (NAE), which is based on body area, is recommended for use in pediat‐
ric patients [43]. PRAL is calculated by the formula (mEq/d) = 0.49 × protein (g/d) + 0.037 × phos‐
phorus (mg/d) − 0.021 × potassium (mg/d) − 0.026 × magnesium (mg/d) − 0.013 × calcium (mg/d) 
[43]. As the formula indicates, dietary protein and phosphorus have acidic effects, whereas 
potassium, magnesium, and calcium have alkaline effects.
3. Medical treatment
When dietary modification is insufficient for metaphylaxis of urinary stones, medical treat‐
ment must be a part of the plan.
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3.1. Alkalizing agents
Urine alkalization is used to reduce recurrence of calcium oxalate, uric acid, and cysteine 
stones, and urine acidification is used to reduce recurrence of infection and calcium‐phos‐
phate stones. For urine alkalization, potassium citrate is chosen instead of sodium citrate 
because sodium causes hypercalciuria. Potassium citrate directly dissolves calcium‐oxalate 
crystals [44]. Therefore, it has a protective effect, even on calcium‐oxalate stones that have 
normal citrate levels. Potassium‐citrate tablets are available in 5 and 10‐mEq doses, and 
Shohl’s citrate‐containing solution, which contains 1 mEq of base per millimeter, may be used 
for infants and children who cannot use tablets.
For calcium‐oxalate stones, the targeted urine pH is 6.5, because uric acid cannot dissolve 
urine pH lower than 5.5, as it needs more alkalinity to dissolve. In metaphylaxis for hyperuri‐
cosuria, the targeted pH is also 6.5; however, to dissolve small uric‐acid stones, the targeted 
pH range is 7–7.2 [7]. The daily dose may include 1–3 mEq/kg, depending on the urine pH 
and the primary disease, and the dose may be as high as 5–8 mEq/kg for infants with distal 
RTA [45]. Ideally, three doses a day should be administered, and if only one dose is possible, 
it should be administered in the evening [46].
Alkalization with hydration and potassium citrate has effectively decreased the risk of stones 
in children who are on a ketogenic diet, but these children should be referred to pediatric neu‐
rology for treatment of their primary diseases before beginning alkalization treatment [47]. 
Because cysteine has poor solubility and precipitates when urine pH is between 5 and 7, in 
alkalization therapy, the targeted value of urine pH must be higher than 7.0 [6, 48]. Alkalization 
accompanied by hydration has effectively prevented the recurrence of cysteine stones [49, 50].
Acetazolamide, a carbonic anhydrase inhibitor, inhibits the reabsorption of sodium bicarbon‐
ate through the proximal tubules, thus raising urine pH and potentially resulting in metabolic 
acidosis with prolonged use. Including acetazolamide in citrate therapy at night significantly 
raises urine pH in patients with cysteine and uric‐acid stones, but half of these patients dis‐
continue the drug due to side effects [51]. In addition, high urine pH may lead to calcium‐
phosphate stones [52, 53].
3.2. Specific treatments according to metabolic disorder
3.2.1. Hypercalciuria
3.2.1.1. Thiazide‐type diuretics
Thiazide‐type diuretics are especially indicated for normokalemic idiopathic hypercalciuria, 
which may be either absorptive or renal. Absorptive hypercalciuria may develop as three 
types: type 1, with direct absorption of calcium through the gastrointestinal system; type 2, 
with absorption of calcium associated with 1.25 dihydroxyvitamin D; or type 3, with renal 
calcium and phosphate absorption [54, 55]. Resorptive hypercalciuria is caused by primary 
hyperparathyroidism and develops with increased bone demineralization [54].
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Thiazide‐type diuretics act on the distal tubules, in which 10% of the sodium chloride is reab‐
sorbed by a thiazide‐sensitive Na+/Cl carrier [56]. Salt restriction during the use of thiazide‐
type diuretics decreases its effectiveness. The side effects of using thiazides have been reported 
as hypokalemia, hyperglycemia, hypercalcemia, and renal injury [57, 58]. Hypokalemia occurs 
with high doses [56]. Hyperglycemia may develop when thiazides are used for hypertension, 
but it has not been observed when they are used for hypercalciuria indications [59]. There 
is little evidence of renal injury with prolonged use of low or medium doses [56]. Children 
who develop hypercalcemia during therapy must be examined for underlying, overlooked 
hyperparathyroidism [58]. The initial dose of hydrochlorothiazide is 1 mg/kg. High doses are 
associated with side effects [60]. Starting with a dose of 0.5 mg/kg and then titrating based 
on urine calcium levels enables both effective treatment and avoidance of side effects [61]. 
However, in cases where high doses of hydrochlorothiazide are necessary, including Dent 
disease, close follow‐up for complications is required [60].
In the presence of calcium‐phosphate stones, the possibility of hyperparathyroidism and 
RTA should be investigated [7]. In cases of high calcium and phosphate levels, it may have 
brushite‐type crystallization in a narrow pH range (6.5–6.8) [7]. Carbonate apatite is crystal‐
ized at pH 6.8 or higher and may present with infection stones or calcium‐oxalate stones [7]. 
Hydrochlorothiazide is also effective on brushite stones [7]. However, patients with these 
require urine acidification rather than urine alkalization. Cranberry juice may be recom‐
mended for pediatric patients, because L‐methionine cannot be used for them [6, 7].
In idiopathic hypercalciuria, decreased bone density may affect future bone health [62]. 
Thiazide‐derived diuretics support bone density, even in patients with restricted calcium [63]. 
Studies have suggested that hydrochlorothiazide is beneficial to bone density in children with 
hypercalciuria, but this effect has been reported as limited in older children who are devel‐
oping osteopenia [64, 65]. Controlled studies with larger populations are needed, but early 
hydrochlorothiazide treatment appears to be favorable for bone growth.
3.2.2. Hyperoxaluria
3.2.2.1. Pyridoxine
Pyridoxine is used for primary hyperoxaluria (PH) type 1. PH has three types: type 1, a defi‐
ciency of alanine glyoxylate aminotransferase; type 2, a deficiency of D‐glycerate dehydroge‐
nase; and type 3, a deficiency of 4‐hydroxy 2‐oxoglutarate aldolase [66].
In PH, due to the enzyme deficiency, glyoxylate cannot be converted into glycine in cofactors 
of pyridoxine (vitamin B6). Therefore, excessive oxalate is produced by the lactate dehydro‐
genase enzyme in the liver. Type 1 is the severest form, and accounts for 80% of PH cases 
[67]. Children with PH type 1 may develop nephrocalcinosis and end‐stage renal failure in 
addition to calcium‐oxalate stones. In contrast, in PH type 3, no end‐stage renal failure has 
been reported [68]. If PH is suspected in pediatric patients, it may be diagnosed using urinary 
oxalate values that have been corrected for body area. In children with PH, the normal oxalate 
level in 24‐hour urine is 0.45 mmol/1.73 m2/24‐hour, and it is usually higher than 1 mmol/1.73 
m2/24‐hour. If the oxalate level in 24‐hour urine is higher than 0.7 mmol/1.73 m2/24‐hour in 
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repeated tests, genetic examination should be performed after excluding causes for secondary 
hyperoxaluria. If it is not possible to diagnose with genetic examination despite high suspi‐
cion, enzyme activity should be analyzed in a liver biopsy [69]. In patients diagnosed with PH 
type 1, pyridoxine therapy should be prescribed in addition to hydration and citrate therapy. 
In type 1 PH, pyridoxine therapy is effective in 50% of patients and decreases the urinary‐
oxalate level by more than 30% [70]. New studies suggesting multiple effects of pyridoxine 
indicate promising ways to treat patients who have not benefited from existing treatments 
[71]. The initial pyridoxine dose is 5 mg/kg, and depending on the response, it can be titrated 
to 20 mg/kg. Although rare, sensorial neuropathy may develop with high doses [72].
Hyperoxaluria may also develop due to causes that include inflammatory bowel disease, 
short‐bowel syndrome, ethylene‐glycol intoxication, and excessive intake of vitamin C. In 
patients with secondary hyperoxaluria, dietary oxalate and salt restrictions and alkalization 
therapy should be begun, and in resistant patients, pyridoxine therapy should be used [6]. 
The initial dose of pyridoxine may be 2–5 mg/kg/day, and it can be titrated to 8–10 mg/kg/day.
3.2.3. Hyperuricosuria
3.2.3.1. Allopurinol
Hyperuricosuria occurs when uric acid is higher than 10 mg/kg in 24‐hour urine [6]. Urinary 
excretion of uric acid is high in infants [26]. In acidic urine, solubility of uric acid is decreased. 
This is more apparent when pH is lower than 5.8 [6]. Hyperuricosuria not only causes uric‐
acid stones but also plays a role in forming calcium‐oxalate stones through epistaxis [31]. 
If hydration and alkalization fail, allopurinol could be begun, particularly in children who 
have hyperuricosuria with hyperuricemia. Allopurinol inhibits the xanthine dehydrogenase 
enzyme, thereby decreasing the concentration of uric acid and increasing the concentration 
of xanthine in the urine [26]. The pediatric dose is 10 mg/kg [6]. Skin rashes may be seen, and 
very rarely, allopurinol hypersensitivity syndrome (AHS) may develop [73]. AHS is a fatal 
side effect that also includes a rash (Stevens‐Johnson syndrome, toxic epidermal necrosis), 
eosinophilia, leukocytosis, hepatitis, fever, and renal failure [73]. This fatal complication has 
no specific treatment other than termination of treatment and support therapy [73]. Therefore, 
it is very important to educate patients and families about symptoms and to make an early 
diagnosis. To prevent such complications, it may be useful to begin with a low dose and 
increase it [73].
Hypoxanthine guanine phosphoribosyl transferase (HPRT) is a purine metabolism enzyme. 
HPRT deficiency, the severest form of which is Lesch‐Nyhan syndrome, may occur with neu‐
rologic symptoms, mental retardation, and nephropathy, and in the early stages of life, kid‐
ney stones [74]. Deficiency of glucose‐6‐phosphate dehydrogenase leads to hyperuricemia, 
increasing the intracellular phosphoribosyl pyrophosphate in type 1 [75]. In both of these 
metabolic diseases, allopurinol therapy is indicated for hyperuricemia and hyperuricosuria. 
In addition to metabolic diseases, myeloproliferative diseases may also cause hyperuricos‐
uria, and in children with hyperuricosuria who develop new stones and for whom hydration 
and alkalization are insufficient, allopurinol may be begun at 10 mg/kg [6].
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Furthermore, deficiency of adenosine phosphoribosyl transferase (APRT), a purine metabo‐
lism enzyme, converts adenine into 8‐hydroxyadenine and xanthine dehydrogenase enzyme 
into 2,8‐dihydroxyadenine (DHA) [76]. Transfer of DHA into the urine is high, and its solubil‐
ity is low, even in alkaline urine, so DHA stones form. Alkalization therapy is not useful in 
such cases, and therapy must consist of 5–10 mg/kg of allopurinol and sufficient hydration [77].
Xanthinuria has two types: type 1 develops with a deficiency of xanthine dehydrogenase 
enzyme and type 2 develops with a deficiency of aldehyde oxidase enzyme [78]. These two 
types are differentiated using an allopurinol test [78]. In addition, xanthinuria may develop 
after Lesh‐Nyhan syndrome is treated using allopurinol [79]. Xanthinuria has no specific treat‐
ment but responds well to hydration, urine alkalization, and reduction of dietary purine [80].
3.2.4. Cystine stones
3.2.4.1. Drugs containing thiol
Cystinuria is a genetic disease in which reabsorption of cysteine and other dibasic amino 
acids, including ornithine, arginine, and lysine, through the proximal tubules is impaired 
[81]. Cystinuria has two genetic types: type 1, which is caused by the SLC3A1 gene on the 
2nd chromosome and type 2, which is caused by the SLC7A9 gene on the 19th chromosome 
[82]. Cystinuria is more common in Eastern Mediterranean populations [83]. Cysteine higher 
than 50 mg/1.73 m2 in 24‐hour urine is considered as a diagnostic for cystinuria [26]. Where 
hydration and alkalization fail, use of thiol‐containing drugs is recommended [6]. Thiol forms 
a disulfide complex, which is soluble with cysteine and prevents formation of stones. Thiol‐
containing drugs are more effective on alkaline urine, and a study has demonstrated that dis‐
solution in urine incubated with cysteine was low for the first 60 minutes when the pH was 
6, but it was optimal when the pH was 8 [84]. However, no difference was found between pH 
7 and 8 after either 60 minutes or 48 hours [84]. This indicates the importance of alkalization 
even when using thiol‐containing drugs. However, a high urine pH may lead to phosphate 
crystallization; therefore, pH 7–7.5 appears to be the most appropriate target.
D‐penicillamine is a chelating agent that contains thiol and increases cysteine dissolution by 
as much as 50‐fold [85]. D‐penicillamine may cause bonemarrow suppression, proteinuria, 
skin eruptions on the neck and extremities, arthralgia, liver dysfunction, and febrile reaction 
[86]. Its use for metaphylaxis of cysteine stones is restricted by the fact that up to 86% of pedi‐
atric patients using it have developed side effects [87]. Although d‐penicillamine use is not 
recommended in children, if it must be used, close follow‐up for side effects is essential. In 
addition, to decrease side effects and increase tolerance, during the first week, the dose should 
be 5 mg/kg/day, and then it should be increased by 5 mg/kg/day, reaching 20 mg/kg/day at 
the end of four weeks [86]. Pyridoxine deficiency develops with long‐term d‐ penicillamine 
therapy, so therapy should include pyridoxine [85].
Alfa mercaptopropionylglycine (AMG, thiopronin) has an effect similar to that of d‐penicil‐
lamine but with fewer side effects [85]. The daily dose is 10–15 mg/kg [6]. The rate of treat‐
ment discontinuation is lower than that for d‐penicillamine therapy [88]. Although thiopronin 
has fewer side effects than penicillamine, patients must be closely monitored for side effects, 
including fever, which often occurs during the first month, rash, bone marrow suppression, 
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and nephrotic syndrome, which improves when the drug is ceased [89, 90]. One uncontrolled 
study suggested that giving a low dose or a dose every other day was effective and further 
decreased the side effects [91]. Use of thiopronin is recommended for pediatric patients when 
hydration and alkalization are not adequate to decrease cystinuria [6].
Adding captopril to cysteine makes the cysteine more than 200 times soluble in urine [86]. 
However, it lowers the concentration of captopril in the urine, making this treatment less 
effective than AMG or d‐penicillamine [92, 93]. Case reports have shown that this treatment 
is effective in pediatric patients and has relatively few side effects, but some studies have also 
indicated the opposite [94–96]. The EAU’s pediatric urology guidelines do not recommend 
the treatment, but it may be considered when AMG cannot be used because of side effects or 
in children with hypertension and proteinuria [6].
3.2.5. Infection stones
Infection stones are stones of struvite, carbonate apatite, or ammonium urate. Urease‐positive 
bacteria increase urinary bicarbonate and ammonium, making urine basic [7]. Unlike acidic 
stones, ammonium‐urate stones form in basic environments and are associated with urinary 
tract infections [7]. In the case of infection stones, the carbonate‐apatite form of calcium phos‐
phate crystalizes at pH 6.8 or higher [7].
In metaphylaxis of infection stones, the primary objective is complete elimination of the 
stones. If a renal anomaly is causing stasis, it should be treated. Use of urease inhibitors is con‐
troversial, even in adult patients, due to their high rate of complications, and L‐methionine 
for urine acidification is not recommended in children [6, 7]. Intake of cranberry juice may be 
recommended for urine acidification in pediatric patients. Antibiotic therapy and prophylaxis 
may be begun if required, along with urinary‐culture follow‐up.
4. Conclusions
Frequent recurrence of urinary stones after initial treatment makes metaphylaxis crucial in chil‐
dren. Suitable metaphylaxis must be preceded by complete metabolic evaluation. Increasing 
fluid intake and optimizing the diet are the first steps in urinary‐stone metaphylaxis. When 
these measures are not sufficient, medical treatment must be added. Most recommendations 
for metaphylaxis in children are based on studies involving adults, and, therefore, more stud‐
ies involving children are called for.
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